Motion Sickness clinical trials
The registry lists 50 studies for Motion Sickness across more than 10 countries. 9 are recruiting or about to start. 40 of them are mainly about Motion Sickness (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20.
Get an email when these change. Save the Motion Sickness studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Repurposed Therapeutics, Inc. (9) · Vanda Pharmaceuticals (4) · Medical Corps, Israel Defense Force (4) · University Hospital, Caen (2) · University of Wisconsin, Madison (2) · Abant Izzet Baysal University (2) · Istinye University (1) · GlaxoSmithKline (1)
What is being tested here
Drugs under test in Motion Sickness studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Antiemetics 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Sep 2027Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness · Phase 3 · Vanda Pharmaceuticals
- Mar 2027StableEyes With Active Neurofeedback · Johns Hopkins University
Who these studies take
Of the 5 Motion Sickness studies recruiting now, 1 (20%) set no upper age limit and 4 (80%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (60%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (80%) | 4 (80%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 4 (80%) | 4 (80%) |
| 75 | 1 (20%) | 1 (20%) |
| 85 | 1 (20%) | 1 (20%) |
Across all 50 studies, recruiting or not: 76% stop at 75 or younger and 58% at 65; 4% take children; 2% are for women only and 4% for men only; 66% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Motion Sickness studies take
Of 15 interventional studies with no phase under Motion Sickness, half reached primary completion within 17 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 17 mo3–29 · 15 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Newly registered1
- Vagal Auricular Stimulation for Motion SicknessOct 14, 2026NCT07873164
Studies
Recruiting first, then most recently updated. Showing 50 of 50. search them.
- Virtual Reality Sickness Questionnaire: Psychometrics in Stroke PatientsEnrolling by invitationNCT072978621 country
- Vagal Auricular Stimulation for Motion SicknessNot yet recruitingNCT07873164Not applicable1 country
- StableEyes With Active NeurofeedbackRecruitingNCT05622344Not applicable1 country
- Motion Sickness Severity and Sensorimotor PerformanceNot yet recruitingNCT07619469
- OKT With Gaze and Postural Stabilization on Vertigo, MS and QOL in VBHNot yet recruitingNCT07575074Not applicable1 country
- Optokinetic Virtual Reality Stimulation in Unilateral Vestibular HypofunctionRecruitingNCT06517446Not applicable1 country
- Evaluation of a Device to Reduce Motion Sickness and Spatial DisorientationRecruitingNCT06892340Not applicable1 country
- Surface Monitoring Technology to Remove The Mask - Stage 1RecruitingNCT04266223Not applicable1 country
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformanceRecruitingNCT05886660Phase 21 country
- Gaze Stabilization vs Oculomotor Exercises on Cybersickness in Computer UsersCompletedNCT07616596Not applicable1 country
- Prevention of Post-Operative Nausea and Vomiting With Propofol InfusionCompletedNCT05759481Phase 21 country
- Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessActive, not recruitingNCT06138613Phase 31 country
- Three-Axis Wearable Adaptive Vestibular StimulatorActive, not recruitingNCT06106256Not applicable1 country
- The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor FunctionCompletedNCT06587386Phase 41 country
- Nebulizer Delivery of Intranasal ScopolamineCompletedNCT04999449Phase 11 country
- Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot StudyCompletedNCT06354309Not applicable1 country
- Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT03772340Phase 21 country
- Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular SchwannomaWithdrawnNCT04196933Not applicable1 country
- Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessCompletedNCT05903924Phase 31 country
- Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT04327661Phase 31 country
- Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional StudyCompletedNCT061287071 country
- Gynecologic Endoscopic Surgery of Female Motion Sickness PatientsCompletedNCT06232785Phase 41 country
- Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity StorageCompletedNCT04213079Not applicable1 country
- Motion Sickness Rehabilitation for Virtual RealityCompletedNCT06056622Not applicable1 country
- Sensory Training for Visual Motion SicknessCompletedNCT04420949Not applicable1 country
- Prevention and Treatment of Nausea Associated With Motion Sickness in Senior SubjectsCompletedNCT03988530Phase 31 country
- Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionCompletedNCT05548270Phase 31 country
- Video Head Impulse Test and Seasickness SusceptibilityCompletedNCT05657340Not applicable1 country
- Seasickness Susceptability and Vestibular Time ConstantCompletedNCT05640258Not applicable1 country
- Motion Sickness Desensitization Using VRStatus unknownNCT05628220Not applicable1 country
- Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness SymptomsCompletedNCT05611814Not applicable1 country
- Sensory Training for Orientation and BalanceWithdrawnNCT04331561Not applicable1 country
- Motion Sickness on Astrolabe's VesselCompletedNCT029114021 country
- Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionCompletedNCT04947423Phase 31 country
- Galvanic Vestibular Stimulation as a Novel Treatment for SeasicknessCompletedNCT05004818Not applicable
- Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical HeterophoriaTerminatedNCT00785135Not applicable1 country
- Meclizine Plasma Levels in Responders and Non-respondersStatus unknownNCT04482985Phase 4
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion SicknessStatus unknownNCT04272255Phase 31 country
- DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion SicknessTerminatedNCT04219982Phase 2/31 country
- The Prevention and Treatment of Nausea Associated With Motion SicknessCompletedNCT03986905Phase 31 country
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion SicknessCompletedNCT04184115Phase 31 country
- Clinical Evaluation of the Use of Ginger Extract in the Management of Motion SicknessCompletedNCT03755596Phase 41 country
- Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going VesselsStatus unknownNCT03920644Phase 31 country
- A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.CompletedNCT02839135Phase 11 country
- Pharmacokinetic and Efficacy Profile Intranasal Scopolamine SprayTerminatedNCT02155309Phase 2/31 country
- Research on Quantification of VR(Virtual Reality) Related Stress and RelaxationStatus unknownNCT02986555Not applicable1 country
- Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy VolunteersCompletedNCT02177890Not applicable1 country
- Levo Phencynonate Hydrochloride for the Prevention of SeasicknessCompletedNCT02241629Phase 21 country
- Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?CompletedNCT00360282Not applicable1 country
- Effects of Transdermal Scopolamine on Occupational PerformanceCompletedNCT00374478Phase 21 country